Authors

  • Marina Cousté
  • François Jonquères

DOI:

https://doi.org/10.5912/jcb9

Keywords:

plea of research, marketing authorisation, clinical trials, generic, infringement, experimental acts

Abstract

This paper discusses a recent French Court decision and its impact on the judicial interpretation of the extent to which pharmaceutical clinical trials may or may not fall within the scope of the exemption provided under French law for infringement of patent rights when conducting unauthorised clinical trials aimed at securing marketing authorisation of a patented drug substance.

Downloads